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a b s t r a c t
Adrenocortical disease (ACD) is a common problem in surgically sterilized, middle-aged to old ferrets (Mustela putorius furo). The adrenal tissues of these ferrets develop hyperplasia, adenomas, or
adenocarcinomas, which produce steroid hormones including estradiol, 17-hydroxyprogesterone, and
androstenedione. Major clinical signs attributable to overproduction of these hormones are alopecia (hair
loss) in both sexes and a swollen vulva in females. Pruritus, muscle atrophy, hind limb weakness, and
sexual activity or aggression are also observed in both sexes. Males can develop prostatic cysts, prostatitis, and urethral obstruction. ACD is thought to be linked to continuous and increased LH secretion, due to
lack of gonadal hormone feedback in neutered ferrets. This continuous elevated LH acts on adrenal cortex LH receptors, resulting in adrenal hyperplasia or adrenal tumor. This study investigated whether the
immunocontraceptive vaccine GonaConTM , a GnRH vaccine developed to reduce the fertility of wildlife
species and the spread of disease, could prevent or delay onset of ACD and treat alopecia in ferrets with
existing ACD. Results showed that GonaCon provided relief from ACD by causing production of antibodies
to GnRH, probably suppressing production and/or release of LH. Treatment caused many ACD symptoms
to disappear, allowing the ferrets to return to a normal life. The study also found that the probability
of developing ACD was signiﬁcantly reduced in ferrets treated with GonaCon when young (1–3 years
old) compared to untreated control animals. GonaCon caused injection site reaction in some animals
when administered as an intramuscular injection but caused few side effects when administered subcutaneously. Both intramuscular and subcutaneous vaccination resulted in similar levels of GnRH antibody
titers. Subcutaneous vaccination with GonaCon is thus recommended to prevent the onset of ACD and as
a possible treatment for ACD-signs in domestic ferrets.
Published by Elsevier Ltd.

1. Introduction
Adrenocortical disease (ACD) is a common problem in neutered,
middle-aged to old pet ferrets (Mustela putorius furo) [6]. It has
been shown that early neutering contributes to ACD [2–4]. Female
domestic ferrets may develop their ﬁrst estrus in spring of the year
following their birth, often between 4.5 and 6 months of age [4].
Once a female has begun an estrus cycle, she may remain in estrus
for an extended period of time if not bred, causing health problems,
such as estrogen-induced anemia. For this reason, pet female ferrets are generally spayed [4]. Because of the musky smell and sexual
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aggressiveness of intact males, most male pet ferrets are castrated
and descented. Most pet ferrets in the U.S. are spayed or castrated
early, between 5 and 7 weeks of age [2,4].
ACD is associated with continuous production of pituitary
luteinizing hormone (LH) due to the lack of negative gonadal
hormone feedback in neutered ferrets. Ferrets and a few other
mammalian species have functional LH receptors in the adrenal
cortex [1]. Therefore, in neutered ferrets, unregulated elevation
of LH stimulates the adrenal LH receptors, resulting in enlarged
adrenals and ACD [1]. Enlarged adrenal glands produce several
sex hormones including estradiol, 17-hydroxyprogesterone, and
androstenedione. In early stages of ACD, these elevated hormones
reduce hair growth in both sexes [3–6], resulting in generalized,
patchy alopecia primarily involving the trunk. Other clinical signs
of ACD are pruritus (itching), muscle atrophy, hind limb weakness,
sexual activity or increased aggression. Males can develop prostatic
cysts, prostatitis, and urethral obstruction. In rare cases, lethal bone
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marrow suppression may occur. The activated adrenal glands frequently develop hyperplasia and may become neoplastic in the
form of adenomas and adenocarcinomas. The malignant tumors
frequently expand and may metastasize, with lethal consequences.
Until recently, surgical removal of affected adrenal gland(s) was
the primary form of treatment for ferret ACD. In the hands of an
experienced veterinary surgeon, removal of the left adrenal is relatively easy and has a low risk associated with the adrenalectomy
surgery. Due to the position of the right adrenal, near several blood
vessels, its removal is more difﬁcult. Surgical intervention of bilateral disease carries signiﬁcant risk of post-operative complications.
In many instances inherent risk concerns related to adrenalectomy,
as well as the cost of surgery, are deterrents to use of surgery to cure
ACD [7].
GnRH agonists can be effective in treating ferrets with ACD.
These agonists have a higher afﬁnity for GnRH receptors than the
endogenous GnRH. When given over long periods of time in a slow
release formulation, agonists cause down-regulation of pituitary
gonadotrophs and signiﬁcantly reduce secretion of LH and FSH.
Two agonists, leuprolide acetate (LupronTM ) and deslorelin acetate
(SuprelorinTM ) have been shown to reduce sex hormones in ferrets and subsequent ACD, resulting in hair regrowth [8–10]. These
agents are effective as long as a threshold concentration of the
agonist can be maintained in the body.
Another product with potential to treat ACD is the immunocontraceptive GnRH vaccine GonaCon, developed as a reproductive
inhibitor for wildlife by the United States Department of Agriculture
(USDA), National Wildlife Research Center (NWRC) [11]. In brief,
the vaccine consists of numerous GnRH peptides conjugated in a
systematic manner to a mollusk hemocyanin protein. This GnRHmollusk conjugate is emulsiﬁed in a water-in-oil emulsion with
a mineral oil adjuvant (AdjuVac) also developed at the National
Wildlife Research Center.
GonaCon vaccine reduces available endogenous GnRH by stimulating production of antibodies that neutralize GnRH released
from the hypothalamus in the vasculature between the hypothalamus and the anterior pituitary gland (add reference). Because of
the reduction in available GnRH, we hypothesize that secretion
of LH and FSH by the anterior pituitary is reduced. In females of
many species [20], follicular development, ovulation, and estrus
are inhibited; in males, testosterone levels are reduced, testicular
size and aggressive behavior decrease signiﬁcantly, and no interest is shown in estrous females. As long as antibody titers to GnRH
are sufﬁciently elevated, reproductive behavior will be suppressed
and the contraceptive effect will last in both sexes [11]. GonaCon has induced contraception with a single shot for 1–6 years
in many mammalian species, including California ground squirrels
(Spermophilus beecheyi) [12], domestic cats (Felis catus) [13], blacktailed prairie dogs (Cynomys ludovicianus) [14], domestic and feral
swine (Sus scrofa) [15,16], wild horses (Equus caballus) [17], bison
(Bison bison) [18], and white-tailed deer (Odocoileus virginianus)
[19].
GonaCon is currently registered with the US Environmental Protection Agency as a contraceptive for use in white-tailed deer and
wild horses. The primary uses of GonaCon are to resolve humanwildlife conﬂicts through management of overabundant wildlife
populations [20] and to prevent disease transmission for sexually
transmitted diseases such as brucellosis [18].
The objectives of this study were:

To test effects of GonaCon on the concentration of steroid hormones in ferrets affected by ACD.
To determine whether GonaCon could be used to treat alopecia in
ferrets affected by ACD.

Table 1
Effect of treatment with GonaCon on hormone concentration in 9 neutered ferrets
diagnosed with adrenal cortical disease (ACD).
Hormone

Estradiol (pmol/L)
Androstenedione (nmol/L)
17-OH progesterone (nmol/L)

Normal
rangea
30–180
1–15
0.5–0.8

Pre-treatment

Post-treatmentb

Mean ± SEM

Mean ± SEM

207(±29.6)
87(±22.3)
7.6(±2.6)

106(±8.5)
6.3(±1.3)
0.28(±0.8)

a

Normal hormone concentration values for ferrets [3,5].
Paired T test run for each hormone, all signiﬁcant at P < 0.05. GonaCon posttreatment samples were drawn 2–3 months after injection.
b

To assess whether GonaCon, administered to juvenile, healthy
ferrets, could be used to prevent the onset of ACD in surgically
sterilized animals.
To test potential side effects and effectiveness of GonaCon administered through intramuscular (IM) or subcutaneous (SC) injection.
2. Materials and methods
2.1. Trial 1: effects of GonaCon as a treatment for ACD
A small study was conducted to determine whether GonaCon
would be effective as a treatment for ACD in ferrets, as measured
by regrowth of hair and decrease in adrenal hormones. Nine ferrets
(3.5–6 years of age) with ACD (showing 100% alopecia and elevated
adrenal sex hormones) were given one 500 g vaccination with
GonaCon intramuscularly using a 22 gauge, ½ inch-long needle in
the neck. Regrowth of hair in these animals was monitored for four
months.
The effect of GonaCon on adrenal hormones was measured
by collecting blood samples from ferrets at vaccination and 2–3
months later. Serum was harvested by centrifugation and stored
frozen at −20 ◦ C until assays were conducted. Pre- and posttreatment serum was sent to the Clinical Endocrinology Service
at The University of Tennessee, College of Veterinary Medicine,
Knoxville, TN, a facility which has validated the radio-immunoassays for adrenal hormone concentrations in ferrets [3]. Serum
samples were analyzed for estradiol, androstenedione, and 17hydroxyprogesterone concentrations, which were compared with
established reference range values for ferrets [3,5] (Table 1). A
paired T test was used to test for differences in pre- and posttreatment hormone levels. Serum was used to determine antibody
titers to GnRH by ELISA methods previously described [21], with the
following changes: 200 ng antigen was used per well and all wells
were blocked with a solution of 20% SEA BLOCK (Thermo Fisher
Scientiﬁc, Rockford, IL, USA) and 5% Tween 20 in 0.01 M PBS.
2.2. Trial 2: effects of GonaCon administered intramuscularly and
subcutaneously to prevent ACD
After determining that treatment with GonaCon could reduce
symptoms of ACD in a manner similar to that observed by use of
deslorelin, a large study was started to determine if GonaCon could
prevent or delay the development of ACD that occurs in middle or
old age ferrets. The hypothesis was that GonaCon could prevent the
uncontrolled elevation of LH in young neutered ferrets and thereby
prevent adrenal hyperplasia and the progressive symptoms of
ACD. Privately-owned ferrets (N = 88) aged 1.0–3.5 years were
enrolled in the study. Spayed females (n = 46) and neutered males
(n = 42) entered into the study were free of health problems during
the initial physical exam; ferrets did not have clinical signs or
behaviors suggestive of adrenocortical disease (e.g., no alopecia,
excessive pruritus, swollen vulva or prostate, stranguria, or signs
of libido). The ferrets remained with the clients so neither diet
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nor photoperiod was standardized during the study. Thirty-three
ferrets were given an IM injection of 0.5 ml (500 g) of GonaCon at
the beginning of the study. Because some of the ferrets vaccinated
IM (see below) developed injection site reactions, the other 55
ferrets in the study were given an SC injection. Boosts were given
SC. The vaccinated ferrets were compared to 125 unvaccinated
ferrets in the same age range that were free of ACD symptoms. The
study was conducted over an eight-year period through records
kept by several exotic pet veterinary clinicians.
Ferrets were vaccinated 1 to 3 times in a 3-year period; 27 ferrets
were vaccinated twice and 13 were vaccinated 3 times. Before vaccination and between 1 and 3 months post vaccination, blood was
collected from a subset of 40 animals for analyses of GnRH antibody
concentrations as described above. A single injection of the vaccine
proved effective in maintaining antibody titers so the remaining
ferrets were not revaccinated. Titers did not differ between animals injected IM or SC so those data were pooled. The cumulative
percentages of control and GonaCon-vaccinated ferrets developing
ACD were plotted as curves. Fischer’s exact test was used to test differences between percentages of ferrets with ACD of control versus
treated ferrets for each year.
2.3. Trial 3: effects of GonaCon administered subcutaneously to
prevent ACD
Occasionally a ferret given an IM injection in the previous study
developed a severe injection site reaction, consisting of sterile
pyo-granulomas, which slowly went away with symptomatic treatment. To determine if SC injections would cause fewer injection site
reactions, 13 neutered ferrets (6 males and 7 females) 2–3 years of
age without signs of ACD were injected subcutaneously with 0.5 ml
(500 g) of GonaCon on the dorsal scruff of the neck and blood
drawn for determination of anti-GnRH titers. One year later ferrets
were clinically evaluated, given a boost injection of GonaCon, and
blood was again drawn. The injection site reactions were examined
and effectiveness of the vaccine was measured through the level of
GnRH antibody titers.
3. Results
3.1. Trial 1: effects of GonaCon administered to ferrets with ACD
Adrenal hormone levels in ferrets with ACD were signiﬁcantly
higher than normal (P < 0.05) (Table 1). Treatment with GonaCon caused adrenal hormones (estradiol, androstenedione and
17-hydroxyprogesterone) to return to their normal range within
3 months following vaccination. The drop in hormone levels was
accompanied by improvement in clinical condition of neutered ferrets. The main clinical improvement was re-growth of hair in early
stages of the disease (Fig. 1). Within 3 months after the GonaCon
vaccination, most ferrets had anti-GnRH titers of 1:128,000. These
high titers were associated with improvement of pelage from total
alopecia (no hair) to 100% body hair (Table 2). Ferrets with lower
titers (1:8000–1:32,000) had less hair growth (20–80% at 2 months)
but still showed improvement, especially 3 months or more after
treatment (60–90%). For other clinical signs of ACD there was a wide
range of responses; many clinical signs, including swollen vulva in
females, and pruritus, muscle atrophy, hind limb weakness, and
sexual activity or aggression, did not completely resolve after the
GonaCon injection.
3.2. Trial 2: effects of GonaCon administered IM or SC to prevent
ACD
Control ferrets developed ACD signiﬁcantly earlier than treated
ferrets. The difference was signiﬁcant for every year but more

Fig. 1. (a) Ferret with normal pelage (100% hair) after GonaCon treatment. (b) Ferret
with alopecia caused by adrenal cortical disease.

pronounced over time (year 1, P < 0.003, years 2–8 P < 0.001). The
percentage of control ferrets (initial n = 125) showing signs of ACD
(and number alive for each year) were 21% (n = 101), 64% (n = 53),
80% (n = 33), and 84% (n = 25) by 2, 4, 6 and 8 years, respectively
(Fig. 2). This compares to percentages for treated ferrets (initial
n = 88) of 1% (n = 86), 8% (n = 79), 20% (n = 49), and 24% (n = 25) at 2,
4, 6 and 8 years, respectively.
Most of the 1–3-month post vaccination titers were 1:128,000
or greater (64.3%), with other animals having titers of 1:8000 (2.4%),
1:32,000 (9.5%), and 1:64,000 (19%). There were 2 nonresponders
(4.8%) with no measurable titers, one of which developed ACD
3 years after vaccination. Titers for ferrets were lower after one
year, with the majority of animals maintaining titers of 1:32,000
to 1:64,000, although some ferrets maintained higher titers of
1:128,000 for 2 years. With a boost, titers increased and were maintained at high levels for a minimum of 2–3 years (80% of ferrets
maintained titers of 1:128,000 or greater).

Table 2
Effect of GonaCon treatment on hair regrowth in 9 ferrets diagnosed with ACD and
showing alopecia. This table shows the relationship of the anti-GnRH titer to hair
regrowth (100% = full hair) at 2 months post treatment and hair growth at >3 months
post-treatment.
2-Month GnRH titer

128,000
128,000
128,000
128,000
128,000
32,000
32,000
32,000
8000

Hair growth
2-Month

≥3-Month

100%
100%
100%
100%
100%
80%
80%
40%
20%

100%
100%
100%
100%
100%
90%
80%
60%
80%

% of ferrets that have developed ACD
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Fig. 2. Cumulative percentage of ferrets vaccinated in an ACD prevention study with
GonaCon (N = 88) versus control animals (N = 125) that developed adrenal cortical
disease over an 8-year period. Fishers’s exact test was performed for each year (year
1, P = 0.04, years 2–8 P < 0.0001).

3.3. Trial 3: effects of GonaCon administered subcutaneously to
prevent ACD
GnRH antibody titers in all 13 ferrets administered GonaCon by
an SC injection were high (1:128,000) one year after treatment. At
this time all ferrets were clinically normal with 100% pelage and no
signs of ACD. At year 2, titer levels for 8 of the ferrets increased to
1:256,000 and titer levels for 5 ferrets remained at 1:128,000. None
of the ferrets had injection site reactions other than an occasional
ﬁrm raised subcutaneous nodule 0.5–1 cm in diameter to either the
prime or boost doses detectable on clinical examination after two
years and none had signs of ACD.
4. Discussion
Clinical signs of ACD in neutered ferrets correlate with increased
levels of LH, which causes loss of body hair (alopecia) and elevated
levels of adrenal hormones in serum. GonaCon in these trials acted
as a treatment and preventive vaccine for ACD by decreasing the
concentration of adrenal steroid hormones.
An advantage of GonaCon is that it provides an immune
response for at least a year based on a single injection. As a
treatment for ACD it was effective within two months following
vaccination, with elevated adrenal sex hormones common to ACD
returning to normal and ferrets with 100% alopecia regaining 60%
or more of their hair within a 4-month period; those animals with
highest GnRH antibody titers regained 100% of their hair and some
resolved other clinical signs. However, GonaCon did not completely
resolve some ACD clinical signs in all ferrets, including complete
hair regrowth, pruritus, swollen vulva or aggressive behavior.
Treatment with GonaCon produces results similar to treatment
with a GnRH agonist (e.g., deslorelin), which is lowering the unregulated elevation of plasma LH. However, the process by which this
is accomplished in the two products is quite different. The GnRH
agonists down-regulate LH receptors to reduce the level of circulating LH. In contrast, GonaCon vaccine reduces the availability of
endogenous GnRH, thereby reducing the GnRH activated release of
LH, and reducing levels of circulating LH. Deslorelin has been shown
to be effective as a treatment for ACD. This study has shown that
GonaCon is less effective than GnRH agonists (Lupron and deslorelin) in treating ACD, despite reversing alopecia in many animals.
Clinical signs are not resolved as quickly with GonaCon as with the
GnRH agonist. GonaCon is also less effective than deslorelin in treating other clinical signs of ACD, perhaps because once adrenal glands
have become neoplastic, their production of sex hormones becomes
autogenous, no longer dependent upon external stimulation by LH.

GonaCon was most effective in preventing ACD in ferrets that
had not yet developed ACD. In the long-term ACD prevention study,
GonaCon treatment resulted in a signiﬁcant reduction in the percentage of ferrets which developed ACD; by 8 years of age the
difference was striking (84% of untreated ferrets had ACD versus
only 24% of treated ferrets). In many contraceptive studies with
GonaCon in other species [15–21] it has been shown that one injection of GonaCon prevents the release of LH for a year or more.
Both IM and SC injection of GonaCon resulted in antibody
titers that remained elevated for a year or more, providing clinical remission. The SC injections caused fewer and minor injection
site reactions compared to IM injections. Many ferrets were given
a second or third GonaCon injection during yearly clinical exams,
ensuring continued remission from ACD. These ferrets had no injection site reactions relating to the yearly booster.

5. Conclusions
GonaCon has been demonstrated to be an effective, welltolerated vaccine for preventing onset of ACD in ferrets. Although
partially effective as an ACD treatment for ferrets, GonaCon did not
eliminate all signs of ACD. The study also indicated that, to minimize
side effects at the injection site, the vaccine should be administered
SC rather than IM.
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